Treatment of Attention Deficit Hyperactivity Disorder in Children With Medical Comorbidities

Abstract

Dr. Kledzik is Assistant Professor of Clinical Psychiatry and Medical Director, Psychiatry Consult Liaison Service, Riley Hospital for Children, Indiana University School of Medicine, 702 Barnhill Drive, Suite 4300, Indianapolis, IN 46202, E-mail: [email protected]; and Dr. Dunn is Professor of Child Neurology and Psychiatry and Arthur B. Richter Professor, Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, IN. Unless otherwise noted below, each faculty and staff's spouse/life partner (if any) has nothing to disclose. Dr. Kledzik and all editors and staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations pertaining to this educational activity. Dr. Dunn has disclosed that he was a member of the speaker's bureau for McNeil Pharmaceuticals and is the recipient of grant/research support from Lilly and GlaxoSmithKline. The authors have disclosed that the use of bupropion, tricyclic antidepressants, and alpha-2 agonist stimulants for treatment of attention deficit hyperactivity disorder, epilepsy, and tic disorders in children with comorbid conditions has not been approved by the U.S. Food and Drug Administration. Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity. Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute, Inc., designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article(s) and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 80% of the quiz questions correctly. This activity expires on June 30, 2011.